$16.14
0.06% day before yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
ANN6748L1027
Symbol
OFIX

Orthofix International NV Stock price

$16.14
+0.06 0.37% 1M
+5.04 45.41% 6M
-1.32 7.56% YTD
-3.20 16.55% 1Y
-0.88 5.17% 3Y
-22.00 57.68% 5Y
-23.47 59.25% 10Y
-20.37 55.79% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.01 0.06%

Key metrics

Basic
Market capitalization
$639.1m
Enterprise Value
$751.6m
Net debt
$112.4m
Cash
$62.9m
Shares outstanding
39.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.8 | 0.8
EV/Sales
0.9 | 0.9
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
56.3%
Return on Equity
-25.0%
ROCE
-13.9%
ROIC
-15.3%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$818.1m | $829.8m
EBITDA
$-63.7m | $84.7m
EBIT
$-93.4m | $-83.4m
Net Income
$-119.1m | $-89.4m
Free Cash Flow
$-2.9m
Growth (TTM | estimate)
Revenue
4.3% | 3.8%
EBITDA
14.0% | 297.7%
EBIT
-2.1% | -38.3%
Net Income
-0.1% | 29.1%
Free Cash Flow
93.7%
Margin (TTM | estimate)
Gross
68.3%
EBITDA
-7.8% | 10.2%
EBIT
-11.4%
Net
-14.6% | -10.8%
Free Cash Flow
-0.4%
More
EPS
$-3.0
FCF per Share
$-0.1
Short interest
4.0%
Employees
2k
Rev per Employee
$490.0k
Show more

Is Orthofix International NV a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Orthofix International NV Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Orthofix International NV forecast:

9x Buy
82%
2x Hold
18%

Analyst Opinions

11 Analysts have issued a Orthofix International NV forecast:

Buy
82%
Hold
18%

Financial data from Orthofix International NV

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
818 818
4% 4%
100%
- Direct Costs 260 260
4% 4%
32%
559 559
5% 5%
68%
- Selling and Administrative Expenses 554 554
5% 5%
68%
- Research and Development Expense 69 69
6% 6%
8%
-64 -64
14% 14%
-8%
- Depreciation and Amortization 30 30
71% 71%
4%
EBIT (Operating Income) EBIT -93 -93
2% 2%
-11%
Net Profit -119 -119
0% 0%
-15%

In millions USD.

Don't miss a Thing! We will send you all news about Orthofix International NV directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Orthofix International NV Stock News

Neutral
Seeking Alpha
16 days ago
Orthofix Medical Inc. ( OFIX ) UBS Global Healthcare Conference 2025 November 11, 2025 1:15 PM EST Company Participants Massimo Calafiore - President, CEO & Director Julie Dewey - Chief Investor Relations & Communications Officer Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right...
Neutral
Seeking Alpha
23 days ago
Orthofix Medical Inc. ( OFIX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Julie Dewey - Chief Investor Relations & Communications Officer Massimo Calafiore - President, CEO & Director Julie Andrews - Chief Financial Officer Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Petusky - Barrington Research ...
Neutral
Business Wire
24 days ago
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclud...
More Orthofix International NV News

Company Profile

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Head office Curaçao
CEO Massimo Calafiore
Employees 1,616
Founded 1987
Website ir.orthofix.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today